| No | Primary DI | Version or Model | Catalog Number | Device Description | Product Code | Product Code Name | Device Class | Brand Name |
|---|---|---|---|---|---|---|---|---|
| 1 | 00816986020150 | 15g | MSBG1500 | Bioactive Bone Graft Putty | MQV | Filler, Bone Void, Calcium Compound | 2 | UNITE Bioactive Bone Graft |
| 2 | 00816986020143 | 7.5g | MSBG0750 | Bioactive Bone Graft Putty | MQV | Filler, Bone Void, Calcium Compound | 2 | UNITE Bioactive Bone Graft |
| 3 | 00816986020136 | 3.75g | MSBG0375 | Bioactive Bone Graft Putty | MQV | Filler, Bone Void, Calcium Compound | 2 | UNITE Bioactive Bone Graft |
| 4 | 00816986020129 | 18cc | OMP-18 | OSTEOMATRIX+ is a bone graft substitute comprising biphasic mineral granules sus OSTEOMATRIX+ is a bone graft substitute comprising biphasic mineral granules suspended in a porous type I collagen matrix. The device is provided sterile and is to be combined with autologous bone marrow aspirate prior to use to facilitate packing into bony defects. The device provides an osteoconductive scaffold that resorbs and guides host bone regeneration during the healing process. | MQV | Filler, Bone Void, Calcium Compound | 2 | OSTEOMATRIX+ |
| 5 | 00816986020112 | 9cc | OMP-09 | OSTEOMATRIX+ is a bone graft substitute comprising biphasic mineral granules sus OSTEOMATRIX+ is a bone graft substitute comprising biphasic mineral granules suspended in a porous type I collagen matrix. The device is provided sterile and is to be combined with autologous bone marrow aspirate prior to use to facilitate packing into bony defects. The device provides an osteoconductive scaffold that resorbs and guides host bone regeneration during the healing process. | MQV | Filler, Bone Void, Calcium Compound | 2 | OSTEOMATRIX+ |
| 6 | 00816986020105 | 15g | OF003 | Bioactive Bone Graft Putty | MQV | Filler, Bone Void, Calcium Compound | 2 | OSTEOFUSE |
| 7 | 00816986020099 | 7.5g | OF002 | Bioactive Bone Graft Putty | MQV | Filler, Bone Void, Calcium Compound | 2 | OSTEOFUSE |
| 8 | 00816986020082 | 3.75g | OF001 | Bioactive Bone Graft Putty is a synthetic bone void filler comprised of a mixtur Bioactive Bone Graft Putty is a synthetic bone void filler comprised of a mixture of calcium phosphate granules (CaP) and (45S5) bioactive glass granules suspended in a resorbable alkyleneoxide polymer (AOP) carrier that facilitates handling and delivery of the granule components. The device is supplied as putty, pre-loaded in a syringe applicator and packaged in a sterile barrier foil pouch. The device is provided sterile, for single use, in a variety of sizes. | MQV | Filler, Bone Void, Calcium Compound | 2 | OSTEOFUSE |
| 9 | M937710346601 | 71034660 | LOF | Stimulator, Bone Growth, Non-Invasive | 3 | EXOGEN Metatarsal Strap | ||
| 10 | 00816986020020 | 3.75g | SGF-037 | Bioactive Bone Graft Putty is a synthetic bone void filler comprised of a mixtur Bioactive Bone Graft Putty is a synthetic bone void filler comprised of a mixture of calcium phosphate granules (CaP) and (45S5) bioactive glass granules suspended in a resorbable alkyleneoxide polymer (AOP) carrier that facilitates handling and delivery of the granule components. The device is supplied as putty, pre-loaded in a syringe applicator and packaged in a sterile barrier foil pouch. The device is provided sterile, for single use, in a variety of sizes. | MQV | Filler, Bone Void, Calcium Compound | 2 | SIGNAFUSE |
| 11 | 00816986020013 | 7.5g | SGF-075 | Bioactive Bone Graft Putty is a synthetic bone void filler comprised of a mixtur Bioactive Bone Graft Putty is a synthetic bone void filler comprised of a mixture of calcium phosphate granules (CaP) and (45S5) bioactive glass granules suspended in a resorbable alkyleneoxide polymer (AOP) carrier that facilitates handling and delivery of the granule components. The device is supplied as putty, pre-loaded in a syringe applicator and packaged in a sterile barrier foil pouch. The device is provided sterile, for single use, in a variety of sizes. | MQV | Filler, Bone Void, Calcium Compound | 2 | SIGNAFUSE |
| 12 | 00816986020006 | 15g | SGF-150 | Bioactive Bone Graft Putty is a synthetic bone void filler comprised of a mixtur Bioactive Bone Graft Putty is a synthetic bone void filler comprised of a mixture of calcium phosphate granules (CaP) and (45S5) bioactive glass granules suspended in a resorbable alkyleneoxide polymer (AOP) carrier that facilitates handling and delivery of the granule components. The device is supplied as putty, pre-loaded in a syringe applicator and packaged in a sterile barrier foil pouch. The device is provided sterile, for single use, in a variety of sizes. | MQV | Filler, Bone Void, Calcium Compound | 2 | SIGNAFUSE |
| 13 | 00816986020037 | IFBG100 | IFBG100 | INTERFACE is a synthetic bioactive bone graft for use in the repair of osseous d INTERFACE is a synthetic bioactive bone graft for use in the repair of osseous defects. It is supplied as irregular synthetic granules of bioactive glass (45S5 Bioglass), sized from 200 microns to 420 microns. When implanted in living tissue, the material undergoes a time dependent surface modification. The surface reaction results in the formation of a calcium phosphate layer, which is equivalent in composition and structure to the hydroxyapatite found in bone mineral. The biological apatite layer of the granules provides an osteoconductive scaffold for the generation of new osseous tissue. New bone infiltrates around the granules allowing the repair of the defect as the granules are absorbed. | MQV | Filler, Bone Void, Calcium Compound | 2 | INTERFACE |
| 14 | 00816986020518 | 200X25X8 MM, 40 CC | SGFS-040 | SIGNAFUSE Bioactive Bone Graft is a bioactive bone graft substitute comprising b SIGNAFUSE Bioactive Bone Graft is a bioactive bone graft substitute comprising biphasic mineral granules and 45S5 bioactive glass suspended in a porous type I collagen matrix. The device is provided sterile and is to be combined with autologous bone marrow aspirate prior to use to facilitate packing into bony defects. The device provides an osteoconductive scaffold that resorbs and guides host bone regeneration during the healing process. | MQV | Filler, Bone Void, Calcium Compound | 2 | SIGNAFUSE Bioactive Bone Graft |
| 15 | 00816986020501 | 100X25X8 MM, 20 CC | SGFS-020 | SIGNAFUSE Bioactive Bone Graft is a bioactive bone graft substitute comprising b SIGNAFUSE Bioactive Bone Graft is a bioactive bone graft substitute comprising biphasic mineral granules and 45S5 bioactive glass suspended in a porous type I collagen matrix. The device is provided sterile and is to be combined with autologous bone marrow aspirate prior to use to facilitate packing into bony defects. The device provides an osteoconductive scaffold that resorbs and guides host bone regeneration during the healing process. | MQV | Filler, Bone Void, Calcium Compound | 2 | SIGNAFUSE Bioactive Bone Graft |
| 16 | 00816986020495 | 50X25X8 MM, 10 CC | SGFS-010 | SIGNAFUSE Bioactive Bone Graft is a bioactive bone graft substitute comprising b SIGNAFUSE Bioactive Bone Graft is a bioactive bone graft substitute comprising biphasic mineral granules and 45S5 bioactive glass suspended in a porous type I collagen matrix. The device is provided sterile and is to be combined with autologous bone marrow aspirate prior to use to facilitate packing into bony defects. The device provides an osteoconductive scaffold that resorbs and guides host bone regeneration during the healing process. | MQV | Filler, Bone Void, Calcium Compound | 2 | SIGNAFUSE Bioactive Bone Graft |
| 17 | 00816986020488 | 25X25X8 MM, 5 CC | SGFS-005 | SIGNAFUSE Bioactive Bone Graft is a bioactive bone graft substitute comprising b SIGNAFUSE Bioactive Bone Graft is a bioactive bone graft substitute comprising biphasic mineral granules and 45S5 bioactive glass suspended in a porous type I collagen matrix. The device is provided sterile and is to be combined with autologous bone marrow aspirate prior to use to facilitate packing into bony defects. The device provides an osteoconductive scaffold that resorbs and guides host bone regeneration during the healing process. | MQV | Filler, Bone Void, Calcium Compound | 2 | SIGNAFUSE Bioactive Bone Graft |
| 18 | M937710344011 | 71034401 | 71034401 | Replacement Main Operating Unit (MOU) for the EXOGEN Ultrasound Bone Healing Sys Replacement Main Operating Unit (MOU) for the EXOGEN Ultrasound Bone Healing System, device identifier M937710344001. | LOF | Stimulator, Bone Growth, Non-Invasive | 3 | EXOGEN® Ultrasound Bone Healing System MOU |
| 19 | M937710346011 | 71034601 | 71034601 | Replacement MOU for the EXOGEN® Ultrasound Bone Healing System, device identifie Replacement MOU for the EXOGEN® Ultrasound Bone Healing System, device identifier M937710346001. | LOF | Stimulator, Bone Growth, Non-Invasive | 3 | EXOGEN® Ultrasound Bone Healing System |
| 20 | M937710346001 | 71034600 | 71034600 | The EXOGEN device provides non-invasive therapy for healing non-unions and accel The EXOGEN device provides non-invasive therapy for healing non-unions and accelerating time to healing of fresh fractures. The EXOGEN Ultrasound Bone Healing Systems has been designed both for use with conservatively treated fresh fractures and non-unions or surgically treated non-unions. The device transmits a low intensity ultrasound signal to the fracture site through coupling gel, with little or no sensation felt by the patient during the treatment. The low-intensity pulsed ultrasound has been shown in in-vitro and in-vivo studies to stimulate cells to produce growth factors and proteins that are important to bone healing. The patient administers treatment at home or at work, once daily, for 20 minutes, or as prescribed by a physician. The device automatically alerts the patient in case of improper application or device performance. The EXOGEN Ultrasound Bone Healing System consists of one main operating unit, gel bottles and strap. The main operating unit provides the treatment control circuitry, the primary battery supply, and monitors the operation of the transducer at the fracture site. The signal specifications cannot be changed. | LOF | Stimulator, Bone Growth, Non-Invasive | 3 | EXOGEN® Ultrasound Bone Healing System |
| 21 | M937710344001 | 71034400 | 71034400 | The EXOGEN Ultrasound Bone Healing System provides non-invasive therapy for heal The EXOGEN Ultrasound Bone Healing System provides non-invasive therapy for healing non-unions and accelerating time to healing of fresh fractures. EXOGEN is designed both for use with conservatively treated fresh fractures and non-unions, or surgically-treated non-unions. EXOGEN transmits a low-intensity ultrasound signal to the fracture site through coupling gel, with little or no sensation felt by the patient during the treatment. Low-intensity pulsedultrasound has been shown in in-vitro and in-vivo studies to stimulate cells to produce growth factors and proteins that are important to bone healing.The patient administers treatment at home or at work, once daily, for 20 minutes, or as prescribed by a physician. EXOGEN automatically alerts the patient in case of improper application or performance. The EXOGEN Ultrasound Bone Healing System consists of one EXOGEN device, a charger, a gel bottle and strap. The EXOGEN device provides the treatment control circuitry, the battery supply and monitors the operation of the transducer at the fracture site. Thesignal specifications cannot be changed. | LOF | Stimulator, Bone Growth, Non-Invasive | 3 | EXOGEN® Ultrasound Bone Healing System |
| No | Primary DI | Version or Model | Catalog Number | Device Description | Brand Name | Organization Name |
|---|---|---|---|---|---|---|
| 1 | 00817337000111 | 630254 | Mitek Orthovisc, 2 mL, US | Orthovisc | ANIKA THERAPEUTICS, INC. | |
| 2 | 00817337000104 | 690016 | Crosslinked Sodium Hyaluronate 22 mg/mL | Monovisc | ANIKA THERAPEUTICS, INC. | |
| 3 | 00816986020808 | 1082020 | 1082020 | DUROLANE is a clear, transparent, viscous gel of highly purified, stabilized, no DUROLANE is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA® technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL. DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. | DUROLANE | BIOVENTUS LLC |
| 4 | 00627843737810 | 024 | Euflexxa | 9902392 CANADA INC | ||
| 5 | 00358468019103 | 002390 | Acid, Hyaluronic, Intraarticular | Synvisc® | GENZYME CORPORATION | |
| 6 | 00357844181137 | 57844-181 | 57844-181 | prefilled syringe | SYNOJOYNT | TEVA PHARMACEUTICALS USA, INC. |
| 7 | 00087541300912 | 00-1111-001-00 | 00-1111-001-00 | Gel-One is a cross-linked hyaluronate hydrogel that is indicated for the treatme Gel-One is a cross-linked hyaluronate hydrogel that is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to non-pharmacologic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics (e.g., acetaminophen). Gel-One is physician-administered, and is injected directly into the cavity of the knee joint. It is delivered via a single-use, pre-filled disposable glass syringe containing 3 mL of Gel-One. | Gel-One® Cross-linked Hyaluronate | SEIKAGAKU CORPORATION |
| 8 | 75060432190001 | None | Orthovisc | FCL HEALTH SOLUTIONS LTD | ||
| 9 | 54158041000006 | 024 | Euflexxa | 9902392 CANADA INC | ||
| 10 | 45060432190000 | NA | Euflexxa | FCL HEALTH SOLUTIONS LTD | ||
| 11 | 35060432190003 | None | injectable (hyaluronic acid, intra-articular) | HYALGAN | FCL HEALTH SOLUTIONS LTD | |
| 12 | 25060432190006 | HYLAN GF-20 | injectable (hyaluronic acid, intra-articular) | SYNVISC | FCL HEALTH SOLUTIONS LTD | |
| 13 | 20358468019114 | 002401 | Acid, Hyaluronic, Intraarticular | Synvisc-One® | GENZYME CORPORATION | |
| 14 | 15060432190009 | HYLAN GF-20 | Acid, Hyaluronic, Intraarticular | SYNVISC ONE | FCL HEALTH SOLUTIONS LTD | |
| 15 | M717715655550 | 89130-5555-01 | 7156-5555 | SUPARTZ (P980044) is indicated for treatment of pain in osteoarthritis (OA) of t SUPARTZ (P980044) is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. SUPARTZ is a sterile, viscoelastic, non-pyrogenic solution (pH of 6.8-7.8) of highly purified, high molecular weight hyaluronic acid (HA) (620 000-1 170 000 daltons). HA, which is extracted from rooster combs, is a polysaccharide containing repeating disaccharide units of glucuronic acid and N-acetylglucosamine. HA is a common constituent of the extracellular matrix of connective tissues. SUPARTZ is supplied sterile in single-use, pre-filled, disposable plastic syringes, each containing 25 mg of HA dissolved in a Phosphate Buffered Saline (PBS) solution (2.5 mL of 1.0% solution). | SUPARTZ® sodium hyaluronate | SEIKAGAKU CORPORATION |
| 16 | M717715644440 | 89130-4444-1 | 7156-4444 | SUPARTZ FX (P980044) is indicated for treatment of pain in osteoarthritis (OA) o SUPARTZ FX (P980044) is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. SUPARTZ FX is a sterile, viscoelastic, non-pyrogenic solution (pH of 6.8-7.8) of highly purified, high molecular weight hyaluronic acid (HA) (620 000-1 170 000 daltons). HA, which is extracted from chicken combs, is a polysaccharide containing repeating disaccharide units of glucuronic acid and N-acetylglucosamine. HA is a common constituent of the extracellular matrix of connective tissues. SUPARTZ FX is supplied sterile in single-use, pre-filled, disposable plastic syringes, each containing 25 mg of HA dissolved in a Phosphate Buffered Saline (PBS) solution (2.5 mL of 1.0% solution). | SUPARTZ FX sodium hyaluronate | SEIKAGAKU CORPORATION |
| 17 | M71389122496630SAM1 | FID185704 | FID185704 | HYMOVIS® is based on an ultra-pure hyaluronan engineered using a proprietary pro HYMOVIS® is based on an ultra-pure hyaluronan engineered using a proprietary process to increase viscosity, elasticity and residence time without chemical crosslinking.The hyaluronan in HYMOVIS® is derived from bacterial fermentation. HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen). | Hymovis® High Molecular Weight Viscoelastic Hyaluronan, 24mg/3ml syringe | FIDIA FARMACEUTICI SPA |
| 18 | M71389122496630A16 | 89122-4966-30 | 89122-4966-30 | HYMOVIS® is based on an ultra-pure hyaluronan engineered using a proprietary pro HYMOVIS® is based on an ultra-pure hyaluronan engineered using a proprietary process to increase viscosity, elasticity and residence time without chemical crosslinking.The hyaluronan in HYMOVIS® is derived from bacterial fermentation. HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen). | Hymovis® High Molecular Weight Viscoelastic Hyaluronan, 24mg/3ml syringe | FIDIA FARMACEUTICI SPA |
| 19 | M71389122087901SAM1 | M71389122087901SAM1A | FID10000317 | TriLURON (sodium hyaluronate) 1 prefilled syringe - 2 mL, 20mg per 2 mL - Profes TriLURON (sodium hyaluronate) 1 prefilled syringe - 2 mL, 20mg per 2 mL - Professional Sample - Not for Sale | TriLURON | FIDIA FARMACEUTICI SPA |
| 20 | M71389122087901A1 | M71389122087901A13 | 89122-0879-01 | TriLURON (sodium hyaluronate) 1 prefilled syringe - 2 mL, 20mg per 2 mL | TriLURON | FIDIA FARMACEUTICI SPA |
| 21 | M71389122072420A1 | 89122-0724-20 | 89122-0724-20 | Hyalgan® Sodium Hylauronate (20mg/2mL) in the 2mL syringe is indicated for the t Hyalgan® Sodium Hylauronate (20mg/2mL) in the 2mL syringe is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, e.g., acetaminophen. It is a viscous solution of purified natural Sodium Hylauronate (Hyalectin®) in buffered physiological sodium chloride. The sodium hylauronate is extracted from rooster combs. It is given by intra-articular injection in a treatment cycle consisting of five injections given at weekly intervals. Some patients may experience benefit with three injections given at weekly cycles. This has been noted in studies reported in the literature in which patients treated with three injections were followed for 60 days. | Hyalgan® Sodium Hylauronate Pre-filled Syringe - 2mL | FIDIA FARMACEUTICI SPA |
| 22 | M71389122072412A1 | 89122-0724-12 | 89122-0724-12 | Hyalgan® Sodium Hylauronate (20mg/2mL) in the 2mL vial is indicated for the trea Hyalgan® Sodium Hylauronate (20mg/2mL) in the 2mL vial is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, e.g., acetaminophen. It is a viscous solution of purified natural Sodium Hylauronate (Hyalectin®) in buffered physiological sodium chloride. The sodium hylauronate is extracted from rooster combs. It is given by intra-articular injection in a treatment cycle consisting of five injections given at weekly intervals. Some patients may experience benefit with three injections given at weekly cycles. This has been noted in studies reported in the literature in which patients treated with three injections were followed for 60 days. | Hyalgan® Sodium Hyaluronate 2mL Vial | FIDIA FARMACEUTICI SPA |
| 23 | M71389122049663SAM1 | FID185704 | FID185704 | HYMOVIS® is based on an ultra-pure hyaluronan engineered using a proprietary pro HYMOVIS® is based on an ultra-pure hyaluronan engineered using a proprietary process to increase viscosity, elasticity and residence time without chemical crosslinking.The hyaluronan in HYMOVIS® is derived from bacterial fermentation. HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen). It is given by intra-articular injection in two injections given at weekly intervals. | Hymovis® High Molecular Weight Viscoelastic Hyaluronan, 24mg/3ml syringe | FIDIA FARMACEUTICI SPA |
| 24 | M71389122049663A16 | 89122-0496-63 | 89122-0496-63 | HYMOVIS® is based on an ultra-pure hyaluronan engineered using a proprietary pro HYMOVIS® is based on an ultra-pure hyaluronan engineered using a proprietary process to increase viscosity, elasticity and residence time without chemical crosslinking.The hyaluronan in HYMOVIS® is derived from bacterial fermentation. HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen). It is given by intra-articular injection in two injections given at weekly intervals. | Hymovis® High Molecular Weight Viscoelastic Hyaluronan, 24mg/3ml syringe | FIDIA FARMACEUTICI SPA |
| 25 | M713891220496010 | 89122-0496-01 | 89122-0496-01 | HYMOVIS® is based on an ultra-pure hyaluronan engineered using a proprietary pro HYMOVIS® is based on an ultra-pure hyaluronan engineered using a proprietary process to increase viscosity, elasticity and residence time without chemical crosslinking. The hyaluronan in HYMOVIS® is derived from bacterial fermentation. HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen). It is given by intra-articular injection in two injections given at weekly intervals. The product is packaged in a one syringe pack. | Hymovis® High Molecular Weight Viscoelastic Hyaluronan, 24mg/3ml syringe, 1 pack | FIDIA FARMACEUTICI SPA |
| 26 | 10886705025183 | 690-016 | 4 mL, 22 mg/mL High Molecular Weight Hyaluronan | Monovisc | ANIKA THERAPEUTICS, INC. | |
| 27 | 10886705023110 | 630-254 | 2 mL, 15 mg/mL High Molecular weight Hyaluronan | Orthovisc | ANIKA THERAPEUTICS, INC. | |
| 28 | 08033638951057 | GS3111 | INTRA-ARTICULAR HYALURONIC ACID. 1 PRE-FILLED SYRINGE CONTAINING 16.8 mg / 2 mL INTRA-ARTICULAR HYALURONIC ACID. 1 PRE-FILLED SYRINGE CONTAINING 16.8 mg / 2 mL HYALURONIC ACID SODIUM SALT | GELSYN-3 | IBSA FARMACEUTICI ITALIA SRL | |
| 29 | 07640128544210 | 4100 | 1% sodium hyaluronate | Euflexxa | FERRING PHARMACEUTICALS INC. | |
| 30 | 05060604130065 | N/A | Monovisc | ACRE PHARMA LIMITED | ||
| 31 | 05060604130041 | N/A | Synvisc | ACRE PHARMA LIMITED | ||
| 32 | 05060604130034 | NA | Inject into the knee to relieve the pain from osteoarthritis. | Synvisc One | ACRE PHARMA LIMITED | |
| 33 | 05060604130027 | NA | Injected into the knee to relieve the pain from osteoarthritis. | Supartz | ACRE PHARMA LIMITED | |
| 34 | 05060604130010 | NA | Inject into the knee to relieve the pain caused by osteoarthritis. | Orthovisc | ACRE PHARMA LIMITED | |
| 35 | 05060604130003 | NA | Injected into the knee to relieve the pain from osteoarthritis. | Euflexxa | ACRE PHARMA LIMITED | |
| 36 | 05060548950071 | N/A | Durolane | PAVAN TRADING LTD | ||
| 37 | 05060548950064 | None | Euflexxa is injected into the knee to relieve the pain of osteoarthritis. | Euflexxa | PAVAN TRADING LTD | |
| 38 | 05060548950057 | None | Supartz is injected into the knee to relieve the pain of osteoarthritis. | Supartz | PAVAN TRADING LTD | |
| 39 | 05060548950033 | None | Monovisc is injected into the knee to relieve the pain of osteoarthritis. | Monovisc | PAVAN TRADING LTD | |
| 40 | 05060548950026 | None | Orthovisc is injected into the knee joint to cushion and lubricate. | Orthovisc | PAVAN TRADING LTD | |
| 41 | 05060548950019 | None | Synvisc is injected into the knee to alleviate the pain of osteoarthritis. | Synvisc One (Synvisc Three) | PAVAN TRADING LTD | |
| 42 | 05060519180056 | NA | Euflexxa | PROPHARMA-UK LTD | ||
| 43 | 05060519180032 | NA | Synvisc One | PROPHARMA-UK LTD | ||
| 44 | 05060519180025 | NA | Supartz | PROPHARMA-UK LTD | ||
| 45 | 05060519180018 | NA | Orthovisc | PROPHARMA-UK LTD | ||
| 46 | 05060519180001 | NA | Hyalgan | PROPHARMA-UK LTD | ||
| 47 | 05060497630048 | 5 Count | Synvisc | PHARMACEUTICAL HEALTH LIMITED | ||
| 48 | 05060497630031 | NA | Supartz | PHARMACEUTICAL HEALTH LIMITED | ||
| 49 | 05060497630024 | NA | Orthovisc | PHARMACEUTICAL HEALTH LIMITED | ||
| 50 | 05060497630017 | NA | Euflexxa | PHARMACEUTICAL HEALTH LIMITED |